17 Comments

the other day I slapped a link or two on some substacks about the biolab in Reedley Ca ….. with little to no response. While comparing various articles written over about a two week period some things bothered me about the ‘response’ by the 3 letter agencies. One article stated the Feds told the local Fresno Co personnel to suppress the information….. this lab was discovered in Dec 2022 and did not hit the press for almost 6 months…. Another issue I have is initial reports stated in the same warehouse where this occurred PCR tests were being manufactured or were present where at least a dozen pathogens and live mice were present. The FDA did a recall on the ‘PCR’ tests (see attached) which advised people to return them to the same company that distributed them. As a retired cop, this makes no f@#&$ing sense. Those test should be tested for the pathogens which were present in the warehouse.

https://www.fresnobee.com/news/local/article278262808.html

https://www.fda.gov/medical-devices/medical-device-recalls/sml-distribution-llc-recalls-skippack-medical-lab-covid-19-direct-antigen-rapid-tests-are-not

While we’re at it

In the summer of 2018, one of China’s largest domestic vaccine makers sold at least 250,000 substandard doses of vaccine for diphtheria, tetanus, and whooping cough. It was the latest in a slew of scandals caused by poor quality drug products made in China over the last decade. In 2008, the contamination of a raw ingredient imported from China and used to make heparin, a blood-thinning drug, was associated with at least eighty-one deaths the United States.

In 2008, the contamination of a raw ingredient imported from China and used to make heparin, a blood-thinning drug, was associated with at least eighty-one deaths the United States. According to an investigative journalist, fraud and manipulation of quality data is still endemic in Chinese pharmaceutical firms.

Expand full comment

Here's an alert which you can possibly bring to the attention of others at this meeting. Is appropriate for Meryl Nass' portion of the program. A trial balloon for putting a drug into the classification of "vaccine" in order to receive the liability shield and as well to get it on the childhood vaxx schedule therefore guaranteeing uptake for Pharma Cos. and obtain free taxpayer subsidies.

Classic Pharma playbook.

Vote to Add Drug to Childhood Vaccination Schedule Opens Door to Daycare Mandates, Tracking, and Injury Liability Shield

Despite clear statements and acknowledgments by federal officials and several committee members at last week’s Advisory Committee for Immunization Practices (ACIP) meeting that nirsevimab is not a vaccine, this U.S. Food and Drug Administration (FDA) approved drug will essentially be treated as a vaccine by the U.S. Centers for Disease Control (CDC).

This action is due to the CDC committee’s determination that “vaccine” is not well defined in federal statute. Therefore, the new drug manufactured by Sanofi and Astra Zeneca is eligible for inclusion in the federally recommended childhood vaccination schedule and in the federally funded Vaccines for Children Program (VFC).

The ACIP vote to treat the new genetically engineered RSV drug as a vaccine for the purpose of adding it to the recommended childhood vaccination schedule, opens the door to adding the fake vaccine to state mandates for daycare attendance and giving Sanofi and Astra Zeneca a liability shield from vaccine injury lawsuits by adding it to the federal Vaccine Injury Compensation Program (VICP).

......

Nirsevimab is a genetically engineered monoclonal antibody designed to passively provide immunity to RSV and was approved by the FDA for licensure as a drug under the trade name Beyfortus on July 17, 2023.8 9 The basis for licensure was in part the recommendation from the FDA’s Antimicrobial Drugs Advisory Committee (AMDAC), which evaluates data on drug products for use in treating infectious diseases and disorders,10 11 12 rather than the FDA’s Vaccines & Related Biological Products Advisory Committee (VRBPAC), which evaluates scientific evidence for the safety and efficacy of new vaccines, which and has made no such recommendation.

.....

The addition of nirsevimab to the VFC program is likely partly due to its private sector price tag of $495/dose. However, the VFC designation only reduces that cost to $395/dose and was criticized by committee members as too costly.

The VFC’s funding comes through an entitlement program under Section 1928 of the Social Security Act.19 Vaccines administered through the VFC program are at no cost to the child, but are not “free” because VFC funding comes from federal tax dollars and by law each state is required to participate through Medicaid.

More here:

https://www.nvic.org/newsletter/aug-2023/nirsevimab-acip-vote-treated-like-vaccine

Expand full comment
author

Absolutely horrible. May G-d prevent them from carrying out their evil plans.

Expand full comment

People are going to have to rise up- that's the only solution.

Expand full comment

Trade subscriptions?

Expand full comment
author

Yes! Please post or send me your link.

Expand full comment

Click on my username!

Expand full comment

Then I can do subscribe back

Expand full comment

Thanks for doing this Brucha. It’s a Wonderful way of getting us to talk

Expand full comment

Thanks for all your work.

Expand full comment

A great team.

Expand full comment

Don’t you all think we know what is going on? What can this meeting tell us that will help

Expand full comment
author

It’s for everyone’s friends who don’t know yet. People are waking up and need information.

Share it around!

Expand full comment

I am in....sounds great. I have been following all the people you mentioned. I am very interested in helping in anyway I personally can...thank you for all you do. Baruch Hashem

Expand full comment

Is there a way to pre-register for this event? Or just try our luck at the time?

Expand full comment
author

There’s no preregistration. G-d willing hopefully there will be enough room for all who want to join.

Expand full comment

Okay, thanks.

Expand full comment